C3657270||nivolumab
C0919936||treatment-naïve
C0025202||melanoma
C0282461||phase III CheckMate 066 study
C3657270||Nivolumab
C0150755||safety profile
C0010927||dacarbazine
C3665472||chemotherapy
C0919936||treatment-naïve
C0278883||metastatic melanoma
C0282461||CheckMate 066 phase III study
C0936012||analyses
C0008976||CheckMate 066
C0220825||evaluated
C0087111||treatment
C3641780||European Organisation for Research and Treatment of Care (EORTC) Core Quality of Life Questionnaire (QLQ-C30)
C2733251||EuroQoL Five Dimensions Questionnaire
C2733251||EQ-5D
C3889277||multi-step statistical plan
C0936012||analyzed
C0678257||descriptively
C0010362||cross-sectionally
C0023981||longitudinally
C0220825||assessment
C0034394||questionnaires
C1527374||treatment arms
C0010927||dacarbazine
C3657270||nivolumab
C0087111||treatment
C0087111||treated
C3657270||nivolumab
C0010927||dacarbazine
C3657270||nivolumab
C0936012||exploratory analysis
C3657270||nivolumab
C2733251||EQ-5D
C0918012||utility index
C2733251||EQ-5D
C3657270||nivolumab
C0087111||treated
C3657270||nivolumab
C1457887||symptom
C3641780||EORTC QLQ-C30
C0010927||dacarbazine
C0936012||analyses
C3657270||nivolumab
C0010927||dacarbazine
C3641780||EORTC QLQ-C30
C2733251||EQ-5D
C0918012||utility index
C3657270||nivolumab
C0010927||dacarbazine
C0025202||melanoma